ClinicalTrials.govpublic full text
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
hepatocellular carcinoma (hcc), radiotherapy, adjuvant, immune checkpoint inhibitor, tace, narrow margin, hepatocellular carcinoma, radiotherapy, sintilimab, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 896675
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.